Prospective study on the risk of hepatocellular carcinoma among hepatitis C virus‐positive blood donors focusing on demographic factors, alanine aminotransferase level at donation and interaction with hepatitis B virus
Open accessAbstract
The risk for hepatocellular carcinoma (HCC) among asymptomatic hepatitis C virus (HCV) carriers is not well understood. A community‐based prospective study was conducted for over 8 years by record linkage to the Osaka Cancer Registry. The subjects were 1,927 individuals who were positive for anti‐HCV through screening for second‐generation HCV antibody (passive hemagglutination assay: ≥ 2 12) in voluntary blood donation. The risk factors for HCC and interaction between HCV and hepatitis B virus (HBV) infection were evaluated by including additional blood donors: 2,519 individuals positive for hepatitis B virus surface antigen (HBsAg) alone, 25 positive for both anti‐HCV and HBsAg, 150,379 negative for both anti‐HCV and HBsAg. The incidence of HCC (/10 5 person‐years) among the HCV‐positive individuals increased with age in both genders, ranging from 68 to 1,306 among those aged 45–74 years. In the HCV‐positive individuals, the cumulative risk of developing HCC between the ages of 40 and 74 year was 21.6% among males and 8.7% among females. A stepwise increase in risk was noted as the serum alanine aminotransferase level increased or serum cholesterol level at baseline decreased in multivariate Cox proportional hazard analysis. The 9‐year cumulative incidence of HCC among individuals positive for HCV alone, those positive for HBsAg alone and those positive for both was 3.0%, 2.0% and 12.0%, respectively. The age‐and‐sex‐adjusted rate ratio was 126, 102 and 572, respectively, when those negative for both were used as a reference. The results demonstrate an increased risk for HCC among asymptomatic HCV‐positive individuals in Japan. Coinfection with HBV and HCV carried a superadditive risk for HCC. © 2004 Wiley‐Liss, Inc.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Exposure fractions among prevalent liver cirrhosis cases were used as a proxy for population attributable fractions, following the direct method when relative risk is high.
“We used the resulting predicted exposure fractions among prevalent cases as a proxy for PAFs for liver cirrhosis. This follows from the direct method of approximating PAFs:”
From Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis (2014) · cites this paper as [34]
Alcohol consumption, prevalence of hepatitis B and C, and diabetes prevalence have increased in India since 1980.
“as has alcohol consumption, prevalence of hepatitis B and C and diabetes (a major risk factor for nonalcoholic fatty liver disease (NAFLD)) [34].”
From Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis (2014) · cites this paper as [34]
Rising hepatitis C prevalence and a growing obesity epidemic in the UK have likely also played a role in increasing the liver cirrhosis burden over the past two decades.
“Rising hepatitis C prevalence and a growing obesity epidemic in the UK have likely also played a role in increasing the liver cirrhosis burden over the past two decades [34,68,69].”
From Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis (2014) · cites this paper as [34]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Cancer Incidence in Five Continents
(1966) · doi:10.1007/978-3-642-85849-9 · Cited by 5,936 · see citing works
Rising Incidence of Hepatocellular Carcinoma in the United States
El‐Serag, H. B., & Mason, A. C. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401001 · Cited by 2,865 · see citing works
李燕娜 (2016) · Japanese journal of leprosy · doi:10.5025/hansen.85.157 · Cited by 1,359 · see citing works
Confidence interval estimation of interaction
Hosmer, D. W., & Lemeshow, S. (1992) · Epidemiology · doi:10.1097/00001648-199209000-00012 · Cited by 1,239 · see citing works
Kiyosawa, K., Sodeyama, T., Tanaka, E., Gibo, Y., Yoshizawa, K., Nakano, Y., Furuta, S., Akahane, Y., Nishioka, K., Purcell, R. H., et al. (1990) · Hepatology · doi:10.1002/hep.1840120409 · Cited by 1,217 · see citing works
Clinical Outcomes after Transfusion-Associated Hepatitis C
Tong, M. J., El-Farra, N. S., Reikes, A., & Co, R. L. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506013322202 · Cited by 1,193 · see citing works
Risk Factors for Hepatocellular Carcinoma among Patients with Chronic Liver Disease
Tsukuma, H., Hiyama, T., Tanaka, S., Nakao, M., Yabuuchi, T., Kitamura, T., Nakanishi, K., Fujimoto, I., Inoue, A., Yamazaki, H., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199306243282501 · Cited by 1,124 · see citing works
Self-citationIdentification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model
Forns, X., Ampurdanés, S., Llovet, J. M., Aponte, J. Á. N., Quintó, L., Martínez‐Bauer, E., Bruguera, M., Sánchez-Tapias, J. M., & Rodés, J. (2002) · Hepatology · doi:10.1053/jhep.2002.36128 · Cited by 1,123 · see citing works
Yoshida, H., Shiratori, Y., Moriyama, M., Arakawa, Y., Ide, T., Sata, M., INOUE, O., Yano, M., Tanaka, M., Fujiyama, S., et al. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-3-199908030-00003 · Cited by 1,096 · see citing works
The Natural History of Hepatitis C Virus Infection
Thomas, D. L., Astemborski, J. A., Rai, R. M., Anania, F. A., Schaeffer, M., Galai, N., Nolt, K. R., Nelson, K. E., Strathdee, S. A., Johnson, L., et al. (2000) · JAMA · doi:10.1001/jama.284.4.450 · Cited by 1,075 · see citing works
Clinical Outcomes after Hepatitis C Infection from Contaminated Anti-D Immune Globulin
Kenny-Walsh, E. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904223401602 · Cited by 911 · see citing works
Prognosis of Chronic Hepatitis C: Results of A Large, Prospective Cohort Study
Niederau, C., Lange, S., Heintges, T., Erhardt, A., Buschkamp, M., Hürter, D., Nawrocki, M., Kruska, L., Hensel, F., Petry, W., et al. (1998) · Hepatology · doi:10.1002/hep.510280632 · Cited by 632 · see citing works
The Long–Term Pathological Evolution of Chronic Hepatitis C
Yano, M., Kumada, H., Kage, M., Ikeda, K., Shimamatsu, K., INOUE, O., Hashimoto, E., Lefkowitch, J. H., Ludwig, J., & Okuda, K. (1996) · Hepatology · doi:10.1002/hep.510230607 · Cited by 598 · see citing works
Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis
Bisceglie, A. M. D., Goodman, Z. D., Ishak, K. G., Hoofnagle, J. H., Melpolder, J. J., & Alter, H. J. (1991) · Hepatology · doi:10.1002/hep.1840140603 · Cited by 538 · see citing works
Ikeda, K., Saitoh, S., Arase, Y., Chayama, K., Suzuki, Y., Kobayashi, M., Tsubota, A., Kobayashi, M., Nakamura, I., Murashima, N., et al. (1999) · Hepatology · doi:10.1002/hep.510290439 · Cited by 467 · see citing works
Takano, S., Yokosuka, O., Imazeki, F., et al. (1995) · Hepatology · doi:10.1002/hep.1840210308 · Cited by 426 · see citing works
Risk Factors for the Rising Rates of Primary Liver Cancer in the United States
El‐Serag, H. B., & Mason, A. C. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.21.3227 · Cited by 418 · see citing works
Wiese, M., Berr, F., Lafrenz, M., Porst, H., & Oesen, U. (2000) · Hepatology · doi:10.1053/jhep.2000.8169 · Cited by 349 · see citing works
Relation of Interferon Therapy and Hepatocellular Carcinoma in Patients with Chronic Hepatitis C
Imai, Y., Kawata, S., Tamura, S., et al. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-129-2-199807150-00005 · Cited by 340 · see citing works
Seeff, L. B., Hollinger, B. F., Alter, H. J., Wright, E. C., Cain, C., Buskell‐Bales, Z., Ishak, K. G., Iber, F. L., Toro, D. H., Samanta, A. K., et al. (2001) · Hepatology · doi:10.1053/jhep.2001.21905 · Cited by 321 · see citing works
Abrogation of p53-Induced Apoptosis by the Hepatitis B Virus X Gene
Wang, X. W. (2003) · Humana Press eBooks · doi:10.1385/1-59259-079-9:57 · Cited by 320 · see citing works
Non-A, Non-B Post-Transfusion Hepatitis: Looking Back in the Second Decade
Koretz, R. L., Abbey, H., Coleman, E., et al. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-119-2-199307150-00003 · Cited by 236 · see citing works
Interferon therapy prolonged life expectancy among chronic hepatitis C patients
Yoshida, H., Arakawa, Y., Sata, M., Nishiguchi, S., Yano, M., Fujiyama, S., Yamada, G., Yokosuka, O., Shiratori, Y., & Omata, M. (2002) · Gastroenterology · doi:10.1053/gast.2002.34785 · Cited by 235 · see citing works
Sun, C.-A. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg041 · Cited by 234 · see citing works
Yoshizawa, H. (2002) · Oncology · doi:10.1159/000048270 · Cited by 229 · see citing works
Yu, M., Yang, Y., Yang, S.-Y., Cheng, S., Liaw, Y., Lin, S., & Chen, C. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.21.1644 · Cited by 183 · see citing works
Rodger, A. J., Roberts, S., Lanigan, A., Bowden, S., Brown, T., & Crofts, N. (2000) · Hepatology · doi:10.1053/jhep.2000.9714 · Cited by 182 · see citing works
Gordon, S. C., Elloway, R. S., Long, J. C., et al. (1993) · Hepatology · doi:10.1002/hep.1840180609 · Cited by 137 · see citing works
Mattsson, L., Sönnerborg, A. B., & Weiland, O. (1993) · Liver International · doi:10.1111/j.1600-0676.1993.tb00644.x · Cited by 109 · see citing works
Trends in mortality from primary liver cancer in Europe
Vecchia, C. L., Lucchini, F., Franceschi, S., et al. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00052-6 · Cited by 109 · see citing works
Alterations and hypermethylation of thep14ARF gene in gastric cancer
Iida, S., Akiyama, Y., Nakajima, T., Ichikawa, W., Nihei, Z., Sugihara, K., & Yuasa, Y. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20000901)87:5 · Cited by 88 · see citing works
Kasahara, A., Tanaka, H., Okanoue, T., et al. (2004) · Journal of Viral Hepatitis · doi:10.1046/j.1365-2893.2003.00481.x · Cited by 70 · see citing works
Self-citationPredictive Value of Screening Tests for Persistent Hepatitis C Virus Infection Evidenced by Viraemia
Watanabe, J., Matsumoto, C., Fujimura, K., Shimada, T., Nishioka, K., Yoshizawa, H., Okamoto, H., Iizuka, H., Tango, T., Ikeda, H., et al. (1993) · Vox Sanguinis · doi:10.1111/j.1423-0410.1993.tb02148.x · Cited by 68 · see citing works
Self-citationHepatitis B and C Viruses and Hepatocellular Carcinoma
Kew, M. C. (1996) · Clinics in Laboratory Medicine · doi:10.1016/s0272-2712(18)30276-2 · Cited by 44 · see citing works
Natural histories of hepatitis C virus infection in men and women simulated by the Markov model
Tanaka, J., Kumada, H., Ikeda, K., et al. (2003) · Journal of Medical Virology · doi:10.1002/jmv.10406 · Cited by 42 · see citing works
Tanaka, H., Hiyama, T., Tsukuma, H., et al. (1994) · Cancer Causes & Control · doi:10.1007/bf01694754 · Cited by 42 · see citing works
Self-citationOsella, A. R., Misciagna, G., Guerra, V., Chiloiro, M., Cuppone, R., Cavallini, A., & Leo, A. D. (2000) · International Journal of Epidemiology · doi:10.1093/ije/29.5.922 · Cited by 41 · see citing works
Cancer Incidence in Five Continents. Cumulative rate and cumulative risk.
Day, N. E. (1992) · PubMed · Cited by 41 · see citing works
Loss of imprinting of igf2 in renal-cell carcinomas
Oda, H., Kume, H., Shimizu, Y., Inoue, T., & Ishikawa, T. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980130)75:3 · Cited by 33 · see citing works
Tanaka, H., Tsukuma, H., Yamano, H., et al. (1998) · Journal of Epidemiology · doi:10.2188/jea.8.244 · Cited by 25 · see citing works
Self-citationLiu, C., Chen, P., Shau, W., et al. (2003) · Liver International · doi:10.1034/j.1600-0676.2003.00820.x · Cited by 25 · see citing works
The Risk of Hepatitis C Virus Infection Among Blood Donors in Osaka, Japan
Tanaka, H., Tsukuma, H., Hori, Y., et al. (1998) · Journal of Epidemiology · doi:10.2188/jea.8.292 · Cited by 20 · see citing works
Self-citationPresent status of community-based HCV screening in Ikeda-Toyono Region, Osaka Prefecture, 2002
Yasuharu, I. M. A. I., Tanaka, H., Fukuda, K., et al. (2004) · Kanzo · doi:10.2957/kanzo.45.232 · Cited by 6 · see citing works
Self-citationRisk of developing hepatocellular carcinoma according to the titer of antibody to hepatitis C virus.
Hara, M., Mori, M., Hara, T., et al. (2001) · PubMed · Cited by 6 · see citing works
Flagged first, then by citations
Research works printed but not linked: 2
- Tanaka H, Tsukuma H, Kasahara A, Hayashi N, Yoshihara H, Ma- suzawa M, Kanda T, Kashiwagi T, Inoue A, Kato M, Oshima A, Kinoshita Y, et al. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hep- atitis C: a retrospective cohort study of 738 patients. Int J Cancer 2000;87:741-9.
- Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 1998;75:347-54.
Cited by
Sorted by citations
Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis
Mokdad, A. A., Lopez, A. D., Shahraz, S., Lozano, R., Mokdad, A. H., Stanaway, J., Murray, C. J., & Naghavi, M. (2014) · BMC Medicine · doi:10.1186/s12916-014-0145-y · Cited by 1,129 · see citing works
Okamura, T., Tanaka, H., Miyamatsu, N., Hayakawa, T., Kadowaki, T., Kita, Y., Nakamura, Y., Okayama, A., & Ueshima, H. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.01.024 · Cited by 172 · see citing works
Self-citation
- Authors
- Tanaka, H., Tsukuma, H., Yamano, H., Oshima, A., & Shibata, H.
- Affiliations
- Osaka International Cancer Institute (JP)
- Osaka Red Cross Hospital (JP)
- Corresponding author
- Tanaka, Hideo
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2004-08-18
- Volume
- 112
- Issue
- 6
- Pages
- 1075-1080
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2070948213
- Cited by
- 57
- References
- 44
- Citations by year
- 2026: 1 · 2022: 2 · 2021: 4 · 2020: 3 · 2019: 1 · 2018: 3 · 2017: 2 · 2016: 1 · 2015: 2 · 2014: 4 · 2013: 1 · 2012: 4
- FWCI
- 4.02
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- International Journal of Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Hepatitis C virus research
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
- Keywords
- hepatocellular carcinoma, hepatitis C virus, hepatitis B virus, HBV/HCV coinfection, blood donors, alanine aminotransferase, serum cholesterol, age and sex differences, cancer incidence, risk factors
- MeSH terms
- Adult, Aged, Alanine Transaminase, Blood Donors, Female, Follow-Up Studies, Hepatitis B, Hepatitis C, Carcinoma, Hepatocellular, Humans, Japan, Liver Neoplasms, Male, Middle Aged, Prospective Studies, Risk Factors, Incidence, Proportional Hazards Models, Risk Assessment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
